Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment of Advanced GIST

It is indicated for the treatment of adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib
05 Oct 2021
Anticancer agents & Biologic therapy;  Personalised medicine;  Sarcomas

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ripretinib (Qinlock), intended for the treatment of advanced gastrointestinal stromal tumour (GIST) in patients who have received prior treatment with three or more kinase inhibitors.

The applicant for this medicinal product is Deciphera Pharmaceuticals (Netherlands) B.V.

Qinlock will be available as 50 mg tablets. The active substance of Qinlock is ripretinib, an antineoplastic agent and protein kinase inhibitor (ATC code: L01EX19). Qinlock is designed to selectively block the oncogenic KIT and PDGFRA kinases by blocking their active conformation.

The benefits of Qinlock are its ability to prolong the time until disease progression in patients with GIST.

The most common side effects are fatigue, alopecia, nausea, myalgia, constipation, diarrhoea, palmarplantar erythrodysaesthesia syndrome, weight loss and vomiting.

The full indication is:

Qinlock is indicated for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

Qinlock should be prescribed by physicians experienced in the administration of anticancer therapy.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days f rom adoption of the opinion.

This product was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.